GSK Product development pipeline
|
|
|
- Marshall Lyons
- 9 years ago
- Views:
Transcription
1 GSK Product development pipeline November 2015
2 Compound Type ndication Phase MAA NDA/BLA HV^ and nfectious Diseases dolutegravir HV integrase inhibitor + non-nucleoside + rilpivirine reverse transcriptase inhibitor HV infections - two drug maintenance regimen tafenoquine 8-aminoquinoline Plasmodium vivax malaria Relenza i.v. neuraminidase inhibitor (i.v.) influenza cabotegravir cabotegravir gepotidacin ( ) HV integrase inhibitor (long-acting parenteral formulation) HV integrase inhibitor (long-acting parenteral formulation) HV infections HV pre-exposure prophylaxis type 2 topoisomerase inhibitor bacterial infections danirixin chemokine (C-X-C Motif) receptor 2 (CXCR2) antagonist influenza* antisense oligonucleotide hepatitis B nonstructural protein 5B (NS5B) polymerase inhibitor hepatitis C antiviral maturation inhibitor HV infections Respiratory Nucala (mepolizumab) interleukin 5 (L5) monoclonal antibody severe eosinophilic asthma* Submitted S: Nov14 S: Nov14 fluticasone furoate + vilanterol + umeclidinium glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist chronic obstructive pulmonary disease (COPD) mepolizumab interleukin 5 (L5) monoclonal antibody COPD* vilanterol long-acting beta2 agonist COPD muscarinic acetylcholine antagonist, beta2 agonist (MABA) COPD toll-like receptor 7 (TLR7) agonist asthma phosphatidylinositol 3-kinase delta (P3Kδ) inhibitor recombinant human angiotensin converting enzyme tumour necrosis factor receptor-1 (TNFR1) domain antibody danirixin chemokine (C-X-C Motif) receptor 2 (CXCR2) antagonist fluticasone furoate + umeclidinium glucocorticoid agonist + muscarinic acetylcholine antagonist asthma and COPD acute lung injury acute lung injury COPD* asthma COPD overlap syndrome losmapimod p38 kinase inhibitor (oral) COPD* mepolizumab interleukin 5 (L5) monoclonal antibody nasal polyposis* mepolizumab interleukin 5 (L5) monoclonal antibody hypereosinophilic syndrome (HES)* soluble epoxide hydrolase (seh) inhibitor COPD fluticasone furoate muscarinic acetylcholine antagonist, beta2 agonist (MABA) + glucocorticoid agonist COPD
3 continued Compound Type ndication Phase MAA NDA/BLA Oncology NY-ESO-1 autologous engineered TCR-T cells (engineered TCR) sarcoma, multiple myeloma, non-small cell lung cancer, melanoma and ovarian cancer tarextumab 3 notch 2/3 monoclonal antibody pancreatic and small cell lung cancer brontictuzumab 3 notch 1 monoclonal antibody solid tumours and haematological OX40 agonist monoclonal antibody solid tumours and haematological fibroblast growth factor (FGF) ligand trap mesothelioma and non-small cell lung cancer lysine-specific demethylase 1 (LSD1) inhibitor beta cell maturation antigen antibody drug conjugate erb-b2 receptor tyrosine kinase 3 (ErbB3) monoclonal antibody enhancer of zeste homologue2 (EZH2) inhibitor phosphatidylinositol 3-kinase (P3K) beta inhibitor acute myeloid leukemia and small cell lung cancer multiple myeloma solid tumours solid tumours and haematological castration resistant prostate cancer focal adhesion kinase inhibitor mesothelioma BET family bromodomain inhibitor solid tumours and haematological mmuno-inflammation sirukumab interleukin 6 (L6) human monoclonal antibody (s.c.) rheumatoid arthritis sirukumab interleukin 6 (L6) human monoclonal antibody (s.c.) giant cell arteritis antibody (s.c.) antibody (i.v.) antibody (i.v.) granulocyte macrophage colony-stimulating factor monoclonal antibody systemic lupus erythematosus* vasculitis* transplant rejection* rheumatoid arthritis oncostatin M (OSM) monoclonal antibody systemic sclerosis interleukin 7 (L7) receptor monoclonal antibody spleen tyrosine kinase (Syk) inhibitor (topical) lymphocyte activation gene 3 (LAG3) protein monoclonal antibody receptor-interacting protein 1 (RP1) kinase inhibitor chemokine (C-C motif) ligand 20 (CCL20) monoclonal antibody macrophage targeted histone deacetylase inhibitor Rare Diseases Sjogren s syndrome chronic urticaria autoimmune diseases psoriasis, rheumatoid arthritis and ulcerative colitis psoriatic arthritis rheumatoid arthritis ex-vivo stem cell gene therapy adenosine deaminase severe combined immune deficiency (ADA-SCD) Submitted S: May transthyretin (TTR) production inhibitor transthyretin-mediated amyloidosis
4 continued Compound Type ndication Phase MAA NDA/BLA Rare Diseases continued mepolizumab interleukin 5 (L5) monoclonal antibody eosinophilic granulomatosis with polyangiitis* serum amyloid P component (SAP) monoclonal antibody + SAP depleter (CPHPC) amyloidosis ex-vivo stem cell gene therapy metachromatic leukodystrophy ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome ex-vivo stem cell gene therapy beta-thalassemia Vaccines Shingrix (Zoster vaccine) recombinant Herpes Zoster prophylaxis MMR live attenuated measles, mumps, rubella prophylaxis (US) N/A Ebola recombinant viral vector Ebola haemorrhagic fever prophylaxis Group B Streptococcus conjugated Group B streptococcus prophylaxis (maternal immunisation) S. pneumoniae recombinant conjugated Streptococcus pneumoniae disease next generation prophylaxis COPD recombinant non-typeable Haemophilus influenzae and Moraxella catarrhalis prophylaxis Hepatitis C recombinant viral vector hepatitis C virus prophylaxis Malaria next recombinant malaria prophylaxis generation (Plasmodium falciparum) Men ABCWY recombinant conjugated Meningococcal A,B,C,W and Y disease prophylaxis Pseudomonas 5 recombinant pseudomonas infection prophylaxis Shigella conjugated and outer membrane Shigella diarrhea prophylaxis Tuberculosis recombinant tuberculosis prophylaxis RSV recombinant respiratory syncytial virus prophylaxis (maternal immunisation) RSV replication-defective recombinant viral vector respiratory syncytial virus prophylaxis HV recombinant proteins HV infection prophylaxis Other Pharmaceuticals Metabolic retosiban oxytocin antagonist threatened pre-term labour daprodustat prolyl hydroxylase inhibitor anaemia associated with chronic renal ( ) # disease ileal bile acid transport (BAT) inhibitor cholestatic pruritus camicinal motilin receptor agonist delayed gastric emptying Eperzan/Tanzeum (albiglutide) glucagon-like peptide 1 (GLP1) receptor agonist type 1 diabetes losmapimod p38 kinase inhibitor focal segmental glomerular sclerosis* otelixizumab cluster of differentiation 3 (CD3) monoclonal antibody new onset type 1 diabetes daprodustat prolyl hydroxylase inhibitor (topical) wound healing ( ) # transient receptor potential cation channel V4 (TRPV4) antagonist heart failure selective androgen receptor modulator muscle wasting oxytocin (inhaled) oxytocin postpartum hemorrhage
5 continued Compound Type ndication Phase MAA NDA/BLA Dermatology chlorhexidine cationic polybiguanide (topical) umbilical cord care Submitted S: Oct15 Toctino (alitretinoin) retinoic acid receptor modulator chronic hand eczema N/A non-steroidal anti-inflammatory atopic dermatitis and psoriasis mepolizumab interleukin 5 (L5) monoclonal antibody severe atopic dermatitis* umeclidinium Neurosciences muscarinic acetylcholine antagonist (topical) hyperhidrosis* beta amyloid monoclonal antibody geographic retinal atrophy / Alzheimer s disease rilapladib antibody (i.v.) lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor myasthenia gravis* Alzheimer s disease KEY: n-license or other alliance relationship with third party ^ ViiV Healthcare, a global specialist HV company with GSK, Pfizer, nc. and Shionogi Limited as shareholders, is responsible for developing and delivering HV medicines. * Also being developed for indications in another therapeutic area 1 Option-based alliance with sis Pharmaceuticals 2 Option-based alliance with Adaptimmune Ltd. 3 Option-based alliance with OncoMed Pharmaceuticals 4 Option-based alliance with Telethon and Ospedale San Raffaele 5 Option-based alliance with Valneva # USAN name, NN approval pending S Month of first submission A BLA MAA NDA Phase Phase Phase Month of first regulatory approval (for MAA, this is the first EU approval letter) Biological License Application Marketing Authorisation Application (Europe) New Drug Application (USA) Evaluation of clinical pharmacology, usually conducted in volunteers Determination of dose and initial evaluation of efficacy, conducted in a small number of patients Large comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety Pending completion of the proposed divestment of GSK s rights in ofatumumab for autoimmune indications, announced 21 August 2015, ofatumumab s development programmes have been removed from this listing. MAA and NDA/BLA regulatory shown in the table above are those that have been achieved. Future filing dates are not included in this list. Brand names appearing in italics are trademarks either owned by or licensed to the GSK group of companies. Such trademarks are not approved for use by the FDA and EMA with respect to the indications referred to. This document outlines GlaxoSmithKline s drug development portfolio. The content of the drug development portfolio will change over time as new compounds progress from discovery to development and from development to the market. Owing to the nature of the drug development process, many of these compounds, especially those in early stages of investigation, may be terminated as they progress through development. For competitive reasons, new projects in pre-clinical development have not been disclosed and some project types may not have been identified. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK s operations are described under tem 3.D Risk factors in the company s Annual Report on Form 20-F for 2014.
6 Head Office and registered Office GlaxoSmithKline plc 980 Great Western Road Brentford, Middlesex TW8 9GS United kingdom Tel: +44 (0) Registered number:
GSK Product development pipeline
GSK Product development pipeline March 2015 Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party *
Co-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered
Monoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:
Genzyme s Multiple Sclerosis Franchise Featured at AAN
PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:
Autoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
EMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
Covers 60 major critical illnesses. Covers 11 minor critical illnesses. ManuMulti Care
It s a difficult subject to think about, but part of planning for the future is being prepared for the unexpected. Critical illness can happen to anyone, at any time. And it s an unfortunate fact, but
Chapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
A Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
August 28, 2012. Company Update Commerzbank Sector Conference Week
August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG
Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its
Principles of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
Development Pipeline as at 30 June 2013
Line Extensions Cardiovascular Axanum*** Brilinta/ Brilique EUCLID Brilinta / Brilique PEGASUS- TIMI 54 Bydureon EXSCEL # Bydureon Dual Chamber Pen # (dapagliflozin)/ metformin FDC # (dapagliflozin) DECLARE
meeting report on the review of applications for orphan designation
13 June 2014 EMA/COMP/309595/2014 Committee for Orphan Medicinal Products (COMP) Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation June
Long Term Use of Antacid Medications Can Cause an Increased Risk for Osteoporosis and Much More
Long Term Use of Antacid Medications Can Cause an Increased Risk for Osteoporosis and Much More By: Jeremie Pederson D.C., C.S.C.S. Many people are concerned about the FDA news release dated May 25, 2010
Winter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011
Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included
GRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
MEASURING CARE QUALITY
MEASURING CARE QUALITY Region November 2015 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
LCD for Erythrocyte Sedimentation Rate (ESR)
LCD for Erythrocyte Sedimentation Rate (ESR) Applicable CPT Code(s): 85651 Sedimentation Rate, Erythrocyte; Non-Automated 85652 Sedimentation Rate, Erythrocyte; Automated ICD-9 Codes that Support Medical
Protein electrophoresis is used to categorize globulins into the following four categories:
Globulin Globulin is one of the two types of serum proteins, the other being albumin. This generic term encompasses a heterogeneous series of families of proteins, with larger molecules and less soluble
Daiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
Company Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
STEM CELL FELLOWSHIP
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
9. WestLB Deutschland Conference. Frankfurt November 16, 2011
9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
How GSK supports independent medical education
How GSK supports independent medical education GlaxoSmithKline s mission is to help people do more, feel better and live longer. As part of this mission we are embarking on a new initiative in how we support
Chapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
Summary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
Drug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
Medical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
Principles of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
Biologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
Biotest Group. H1 2014 Conference call 12 August 2014
Biotest Group H1 2014 Conference call 12 August 2014 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset
Core therapeutic areas
Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014
The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
Pfizer Pipeline. As of February 27, 2015
Pfizer Pipeline As of February 27, 2015 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses (MOA) information for
Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
BSc in Medical Sciences with PHARMACOLOGY
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
SUMMARY TABLE OF MEASURE CHANGES
Summary Table of Measure 1 SUMMARY TABLE OF MEASURE CHANGES Guidelines for Physician Measurement Effectiveness of Preventive Care Guidelines for Physician Effectiveness of Care Adult BMI Assessment Weight
Immunity and how vaccines work
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
Immuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD
Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer
New Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
Phone: +44 20 8123 2220 Fax: +44 207 900 3970 [email protected] http://marketpublishers.com
Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020
Severe Combined Immune Deficiency (SCID)
Severe Combined Immune Deficiency (SCID) ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Severe combined immune deficiency (SCID) is the most serious form of primary immune deficiency and is usually
Systemic Lupus Erythematosus
Harvard-MIT Division of Health Sciences and Technology HST.021: Musculoskeletal Pathophysiology, IAP 2006 Course Director: Dr. Dwight R. Robinson Systemic Lupus Erythematosus A multi-system autoimmune
Why use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
Solid Organ Transplantation
Solid Organ Transplantation Infection Prevention And Control Transplant Atlantic 2011 October 13/2011 Kathy Hart Introduction In the past several years, the drugs that we use, the surgeries themselves,
How To Get A Chronic Illness Benefit From The Discovery Health Medical Scheme
Cover for medicine and treatment of chronic conditions 2014 Cover for medicine and treatment of chronic conditions 22 November 2013 Page 1 of 16 Cover for medicine and treatment of chronic conditions Overview
This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
Summary of the risk management plan (RMP) for Otezla (apremilast)
EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure
CHAPTER 35 HUMAN IMMUNE SYSTEM STANDARDS:SC.912.L.14.52 & SC.912.L.14.6
CHAPTER 35 HUMAN IMMUNE SYSTEM STANDARDS:SC.912.L.14.52 & SC.912.L.14.6 SECTION 1 - Infectious Disease 1.Identify the causes of infectious disease. 2.Explain how infectious diseases are spread. Causes
Group 2: Critical Illness Benefits
Group 2: Zurich s cover is designed to free yourself and your loved ones from the potentially devastating financial impact that follows diagnosis with a critical illness. 1. Level Term Life or Earlier
CAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal
A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple
LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 03/16/09 for the Period Ending 12/31/08 Address 11085 NORTH TORREY PINES ROAD SUITE 300 LA JOLLA, CA 92037 Telephone 858-550-7500 CIK 0000886163
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
ANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
NORD Guides for Physicians #1. Physician s Guide to. Tyrosinemia. Type 1
NORD Guides for Physicians #1 The National Organization for Rare Disorders Physician s Guide to Tyrosinemia Type 1 The original version of this booklet was made possible by donations in honor of Danielle
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
SUPER CARE CRITICAL ILLNESS PROTECTOR
SUPER CARE CRITICAL ILLNESS PROTECTOR At ACE Life, we are committed to helping our valued customers achieve financial security and have a peace of mind through our comprehensive range of life insurance
Cytokines: Physiology and Clinical Relevance Pranay D. Khare, Ph.D. and Meenakshi Khare, Ph.D.
Cytokines: Physiology and Clinical Relevance Pranay D. Khare, Ph.D. and Meenakshi Khare, Ph.D. A shift in medicine is taking place. It is characterized by the emergence of neuroendoimmunology (NEI), a
Immunization Information for Blinn College Students
1 Immunization Information for Blinn College Students *Important Information Regarding the Bacterial Meningitis Vaccine* The State passed Senate Bill 1107 in 2011 and recently Senate Bill 62 in 2013, which
List of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
What is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection
Module 1 Overview of HIV Infection Purpose Pre-requisite Modules Learning Objectives To provide you with the basic terms and concepts related to HIV infection. None At the end of this module, you will
STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016
STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based
Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812
NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN
New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head
New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May